Renal Cell Carcinoma (gp200) Antibody (HD30)

Product: BTZ043

Renal Cell Carcinoma (gp200) Antibody (HD30) Summary

Immunogen
Purified extracellular domain of human CD205-IgG1 Fc fusion protein.
Specificity
This antibody specifically recognises CD205, otherwise known as DEC205, a type I transmembrane glycoprotein and member of the macrophage mannose receptor family of C-type lectins, predominantly expressed by human dendritic cells.
Isotype
IgG1
Clonality
Monoclonal
Host
Mouse
Gene
LY75
Purity
Protein G purified
Innovators Reward
Test in a species/application not listed above to receive a full credit towards a future purchase.

Learn about the Innovators Reward

Applications/Dilutions

Dilutions
  • Western Blot 1:100-1:2000
  • Flow Cytometry 1:10-1:200
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Frozen 1:10-1:500

Packaging, Storage & Formulations

Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Buffer
PBS (pH 7.4)
Preservative
0.09% Sodium Azide
Concentration
1.0 mg/ml
Purity
Protein G purified

Alternate Names for Renal Cell Carcinoma (gp200) Antibody (HD30)

  • CD205LY-75
  • CLEC13BLy-75
  • C-type lectin domain family 13 member B
  • DEC-205CD205 antigen
  • GP200-MR6
  • lymphocyte antigen 75

Background

gp200 is a surface membrane glycoprotein expressed on human embryonal carcinoma and is a malignant stem cell of testicular tumors. In normal kidney, gp200 is localized along the brush border of the pars convoluta and pars recta segments of the proximal tubule, as well as focally along the luminal surface of Bowmans capsule adjoining the outgoing proximal tubule. Of other normal tissues examined, the gp200 is also localized along the luminal surfaces of breast lobules and ducts, the luminal surface of the epididymal tubular epithelium, within the cytoplasm of parathyroid parenchymal cells, and focally within the colloid of thyroid follicles. Thirty one other normal tissues do not express similar or cross reacting antigens. Reportedly, gp200 is expressed by 93% of primary and 84% of metastatic renal cell carcinomas.

PMID: 3216901